Pollution by the pharmaceutical, healthcare, and agricultural sectors is driving the development of 'superbug' strains of bacteria that have become resistant to every know
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh